Phaseline

Targets › TNFRSF13B

TNFRSF13B (Tumor necrosis factor receptor superfamily member 13B): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Neurology; next expected readout Mar 2029.

Receptor for TNFSF13/APRIL and TNFSF13B/TALL1/BAFF/BLYS that binds both ligands with similar high affinity. Mediates calcineurin-dependent activation of NF-AT, as well as activation of NF-kappa-B and AP-1. (UniProt, O14836)

Open in Phaseline: the race on TNFRSF13B, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Aurinia PharmaceuticalsAritinercept
BAFF receptor (BAFF-R) agonist
TNFRSF13BPhase 1Myasthenia Gravis, GeneralizedMar 2029

Conditions

Myasthenia Gravis, Generalized (1)

Modalities

antibody (1)

Companies

Aurinia Pharmaceuticals (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.